Effect of silibinin on the expression of MMP2, MMP3, MMP9 and TIMP2 in kidney and lung after hepatic ischemia/reperfusion injury in an experimental rat model.
Journal
Acta cirurgica brasileira
ISSN: 1678-2674
Titre abrégé: Acta Cir Bras
Pays: Brazil
ID NLM: 9103983
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
05
2021
accepted:
12
08
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
The protective effect of silibinin on kidney and lung parenchyma during hepatic ischemia/reperfusion injury (IRI) is explored. Sixty-three Wistar rats were separated into three groups: sham; control (45 min IRI); and silibinin (200 μL silibinin administration after 45 min of ischemia and before reperfusion). Immunohistochemistry and real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to evaluate the expression levels of MMP2, MMP3, MMP9, and TIMP2 on kidney and lung. Comparing sham vs. control groups, confirmed that hepatic IRI increased both renal and lung MMP2, MMP3, MMP9 and TIMP2 expressions starting at 180 min (p<0.001). Comparison of the control vs. silibinin groups showed a statistically significant decrease in the expression levels of MMP2, MMP3, and MMP9 and increase of TIMP2 in kidney and lung parenchyma. The starting point of this decrease was at 120 min after reperfusion, both for kidney and lung parameters, and it was statistically significant at 240 min (p<0.001) for kidney, while silibinin showed a peak of lung protection at 180 min after hepatic reperfusion (p<0.001). Hepatic IRI causes distant kidney and lung damage, while a statistically significant protective action, both on kidney and lung parenchyma, is conveyed by the intravenous administration of silibinin.
Identifiants
pubmed: 34755764
pii: S0102-86502021000900203
doi: 10.1590/ACB360904
pmc: PMC8580512
pii:
doi:
Substances chimiques
Timp2 protein, rat
0
Tissue Inhibitor of Metalloproteinase-2
127497-59-0
Silybin
4RKY41TBTF
Matrix Metalloproteinase 3
EC 3.4.24.17
Matrix Metalloproteinase 2
EC 3.4.24.24
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e360904Références
Hippokratia. 2013 Oct;17(4):292-7
pubmed: 25031504
Arch Biochem Biophys. 2014 Oct 1;559:91-9
pubmed: 24946050
Free Radic Biol Med. 2002 Nov 1;33(9):1200-8
pubmed: 12398928
BMC Pharmacol Toxicol. 2020 Jan 23;21(1):8
pubmed: 31973745
IUBMB Life. 2017 Aug;69(8):631-637
pubmed: 28636236
Oxid Med Cell Longev. 2017;2017:8787392
pubmed: 28798861
Prog Mol Biol Transl Sci. 2017;148:1-29
pubmed: 28662821
Clin J Am Soc Nephrol. 2006 Sep;1(5):1066-79
pubmed: 17699328
Prog Mol Biol Transl Sci. 2017;148:31-65
pubmed: 28662825
Cell Physiol Biochem. 2005;16(4-6):147-54
pubmed: 16301815
Am J Transplant. 2007 Jan;7(1):168-76
pubmed: 17109735
Int J Surg. 2013;11(1):96-100
pubmed: 23261946
Mediators Inflamm. 2017;2017:7083528
pubmed: 29440779
Oxid Med Cell Longev. 2014;2014:906965
pubmed: 24799983
J Gastroenterol Hepatol. 2003 Aug;18(8):891-902
pubmed: 12859717
Exp Mol Pathol. 2003 Apr;74(2):86-93
pubmed: 12710939
Clin Sci (Lond). 2011 Sep;121(6):257-66
pubmed: 21463257
High Alt Med Biol. 2017 Sep;18(3):209-218
pubmed: 28459597
World J Gastrointest Surg. 2014 Jul 27;6(7):122-8
pubmed: 25068009
Ren Fail. 2020 Nov;42(1):208-215
pubmed: 32102588
J Hepatol. 2011 Jul;55(1):227-8
pubmed: 21238521
Physiol Rev. 2007 Jan;87(1):69-98
pubmed: 17237343
World J Gastroenterol. 2013 Mar 21;19(11):1683-98
pubmed: 23555157
World J Gastroenterol. 2012 Jan 28;18(4):323-30
pubmed: 22294838
Food Chem Toxicol. 2020 Nov;145:111731
pubmed: 32891719
Ann Surg. 1908 Oct;48(4):541-9
pubmed: 17862242
Acta Chir Belg. 2006 Jan-Feb;106(1):68-72
pubmed: 16612918
Br J Pharmacol. 2002 Nov;137(6):771-81
pubmed: 12411407
Int J Nanomedicine. 2017 Apr 04;12:2689-2702
pubmed: 28435252
Expert Rev Clin Pharmacol. 2016 Oct;9(10):1323-1330
pubmed: 27362364
Shock. 1996 Jan;5(1):34-40
pubmed: 8821101
Food Chem Toxicol. 2016 Oct;96:215-25
pubmed: 27481074
Food Chem Toxicol. 2018 Apr;114:69-77
pubmed: 29432839
Prostaglandins Leukot Essent Fatty Acids. 2006 Jun;74(6):379-83
pubmed: 16698257
Am J Respir Crit Care Med. 1996 Nov;154(5):1364-9
pubmed: 8912749
Liver Transpl. 2003 Jul;9(7):764-71
pubmed: 12827567
J Clin Invest. 1995 Jan;95(1):134-41
pubmed: 7814607
Mol Neurobiol. 2016 Mar;53(2):932-943
pubmed: 25561437
J Invest Surg. 2018 Jun;31(3):201-209
pubmed: 28418711
Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii2-viii4
pubmed: 17890258
Cancer Res. 2005 May 15;65(10):4448-57
pubmed: 15899838
J Trauma. 1997 Oct;43(4):627-33; discussion 633-5
pubmed: 9356059
Am J Respir Crit Care Med. 2019 Jan 15;199(2):181-189
pubmed: 30114376
Exp Ther Med. 2016 Nov;12(5):3181-3188
pubmed: 27882135
Am J Pathol. 2002 Jun;160(6):2111-22
pubmed: 12057915
PLoS One. 2014 Sep 29;9(9):e108855
pubmed: 25264893
J Invest Surg. 2018 Dec;31(6):491-502
pubmed: 28952834
Mol Pharm. 2015 Mar 2;12(3):954-65
pubmed: 25665128
Hippokratia. 2018 Jul-Sep;22(3):99-104
pubmed: 31641330
Sci Rep. 2017 Feb 16;7:42701
pubmed: 28205545
Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):79-89
pubmed: 23229329
Mol Biol Rep. 2012 Dec;39(12):11201-16
pubmed: 23070905
Gastroenterology. 2003 Sep;125(3):917-36
pubmed: 12949736
Anesth Analg. 2008 Oct;107(4):1284-9
pubmed: 18806041
Ann Surg Innov Res. 2010 Mar 26;4:2
pubmed: 20346153
Mol Pharmacol. 2007 Mar;71(3):817-25
pubmed: 17151289
Food Chem Toxicol. 2014 Dec;74:270-8
pubmed: 25455894
Oncotarget. 2017 Jul 11;8(51):89307-89314
pubmed: 29179521
J Surg Res. 2002 Oct;107(2):234-40
pubmed: 12429181
Int J Pharm. 2015 Sep 30;493(1-2):366-73
pubmed: 26222744
Hepatology. 1994 Feb;19(2):354-9
pubmed: 8294093
Lab Invest. 2018 Jan;98(1):51-62
pubmed: 28920945
Liver Transpl. 2007 Mar;13(3):382-90
pubmed: 17318856
Lab Invest. 2009 Feb;89(2):196-208
pubmed: 19079326
Liver Transpl. 2002 Feb;8(2):91-109
pubmed: 11862584